Diethyl-6-(4-hydroxycarbamoyl-phenyl-carbamoyloxymethyl)-naphtalen-2-yl-methyl-ammonium chloride and other derivatives of n-hydroxy-benzamide for use in the treatment of hiv infections

摘要

pHerein disclosed is a method for treating patients affected by HIV comprising administering N-hydroxy-benzamide-based histone deacetylase inhibitors  such as: • diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxymethyl)-naphtalen-2-yl- methyl] -ammonium chloride; • 4-(2-(S)-benzoylamino-3-naphtalen-2-yl-propionylamino)-N-hydroxy- benzamide; and/or • benzo[l 3]dioxole-5-carboxylic acid [l(S)-(4-hydroxycarbamoyl- phenylcarbamoyl)-2-naphtalen-2-yl-ethyl]-amide. Such histone deacetylase inhibitors are administered in a dosage ranging from 50 to 200 mg/day  preferably from 100 to 200 mg/day  so as to obtain a blood concentration between 125 and 250 nM./p